Registration Dossier

Administrative data

Description of key information

A GLP-compliant in vitro skin sensitization turnkey testing strategy was conducted according to OECD Guidelines 442C, 442D and 442E to assess the skin sensitizing potential of the test substance. The three in vitro methods addressed key events of the adverse outcome pathway (AOP) for skin sensitization as defined by the OECD: protein reactivity (DPRA), activation of keratinocytes (LuSens) and activation of dendritic cells (h-CLAT). Based on the positive results observed in the LuSens and the h-CLAT it is concluded that the test substance shows a skin sensitizing potential in this in vitro skin sensitization turnkey test strategy.

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records

Referenceopen allclose all

Endpoint:
skin sensitisation: in chemico
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
May - Jun 2019
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to
Guideline:
OECD Guideline 442C (In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA))
Version / remarks:
04 February 2015
Deviations:
no
GLP compliance:
yes (incl. certificate)
Remarks:
Landesamt für Umwelt Rheinland-Pfalz
Type of study:
direct peptide binding assay
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Expiration date of the lot/batch: 17 Jan 2020
- Physical state / color: solid, white
- Molecular weight: 261.794 g/mol
- Log Kow: - 0.77 (information provided by the sponsor)

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: ambient; under N2
- Solubility and stability of the test substance in the solvent/vehicle: The test substance was soluble in the vehicle.

TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The test substance was prepared as a 100 mM preparation in acetonitrile considering a molecular weight of 261.794 g/mol and a purity / contents of 91.1 %. After short stirring the test substance was soluble in the vehicle.

FORM AS APPLIED IN THE TEST (if different from that of starting material) : solution
Details on study design:
Skin sensitisation (In chemico test system) - Details on study design:
The test substance was dissolved in a suitable vehicle. Three samples of the test substance were incubated with each peptide. Additionally, triplicates of the concurrent vehicle control (= NC) were incubated with the peptides. The remaining non-depleted peptide concentration was determined thereafter by HPLC with gradient elution and UV-detection at 220 nm.
In addition, calibration samples of known peptide concentration, prepared from the respective peptide stock solution used for test-substance incubation, were measured in parallel with the same analytical method.

PREPARATION OF PEPTIDE STOCK SOLUTIONS
Peptide stock solutions in a concentration of 0.667 mM were prepared in pH 7.5 phosphate
buffer (C-containing peptide) or pH 10.2 ammonium acetate buffer (K-containing peptide). The peptide stock solution was used for preparing the calibration samples and the test substance and control samples.

PREPARATION OF THE TEST SUBSTANCE SAMPLES
The samples were prepared in suitable tubes, capped tightly and incubated at 25°C ± 2.5°C in the dark for 24 ± 2 hours. Visual inspection for solubility was performed directly after sample preparation and prior to HPLC analysis. Unsolved samples were centrifuged and/or filtrated prior to injection into the HPLC in order to remove any unsolved particles. The HLPC analysis of the batch of samples started about 24 hours after sample preparation and the analysis time itself did not exceed 30 hours.

PREPARATION OF THE VEHICLE CONTROLS
Several vehicle controls were prepared in triplicates in the same way as the test-substance samples described above but with the vehicle (acetonitrile) instead of the test substance: One set (set A) was analyzed together with the calibration samples without incubation and serves as a performance control. Another three sets (two sets B and set C) were prepared and incubated with the samples. Sets B were placed at the very start and ending of the sample list and serve as stability control of the peptide over the analysis time. Set C was analyzed with the samples and serves for calculation of the peptide depletion of any chemical formulated in the vehicle.

PREPARATION OF THE CO-ELUTION CONTROL
One sample per peptide was prepared in the same way as the test-substance samples
described above but without the peptides. Instead the respective peptide buffer was used. The samples were analyzed together with the calibration samples. Samples which were visually turbid or display precipitates were centrifuged and/or filtrated prior to injection into the HPLC in order to remove any unsolved particles.
Parameter:
other: Mean peptide depletion [%]
Run / experiment:
mean of both depletions
Value:
0.04
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Remarks on result:
no indication of skin sensitisation
Parameter:
other: C-peptide depletion [%]
Run / experiment:
mean
Value:
0
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Remarks on result:
no indication of skin sensitisation
Remarks:
negative results were set to "0"
Parameter:
other: L-peptide depletion [%]
Run / experiment:
mean
Value:
0.08
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Remarks on result:
no indication of skin sensitisation

Table 5: Peptide depletion of NC, PC and the test substance for cysteine-peptide

Reaction with cysteine-peptide

Peptide depletion [%]

Sample 1

Sample 2

Sample 3

Mean

SD

NC: ACN

- 0.05

0.17

- 0.11

0.00

0.15

Test substance

- 0.29

- 0.34

0.28

- 0.12

0.34

PC: EGDMA in ACN

50.31

51.92

53.42

51.88

1.56

Table 6: Peptide depletion of NC, PC and the test substance for lysine-peptide

Reaction with cysteine-peptide

Peptide depletion [%]

Sample 1

Sample 2

Sample 3

Mean

SD

NC: ACN

- 0.19

- 0.62

0.81

0.00

0.74

Test substance

0.00

0.15

0.08

0.08

0.07

PC: EGDMA in ACN

11.47

12.92

13.04

12.48

0.87

Table 7: Mean peptide depletions of Cysteine, Lysine and both peptides

 

Cysteine-Peptide

Lysine-Peptide

Mean of both depletions [%]

Mean depletion [%]

SD [%]

Mean depletion [%]

SD [%]

Test substance

- 0.12

0.34

0.08

0.07

0.04

PC: EGDMA in ACN

51.88

1.56

12.48

0.87

32.18

Conclusions:
Based on the observed results and applying the cysteine 1:10 / lysine 1:50 prediction model it was concluded that the test substance was minimal or no chemical reactivity in the DPRA under the test conditions chosen.
Executive summary:

The reactivity of the test substance towards synthetic cysteine (C)- or lysine (K)-containing peptides was evaluated in the Direct Peptide Reactivity Assay (DPRA). For this purpose, the test substance was incubated with synthetic peptides for ca. 24 hours at ca. 25°C and the remaining non-depleted peptide concentrations were determined by high performance liquid chromatography (HPLC) with gradient elution and UV-detection at 220 nm.

The test substance was dissolved at 100 mM in acetonitrile. Three samples of the test substance were incubated with each peptide in ratios of 1:10 (for C-containing peptide) or 1:50 (for K-containing peptide). Additionally, triplicates of the concurrent vehicle control (= VC) were incubated with the peptides.

Further, in order to detect possible interference of the test substance with the peptides, a coelution control was performed and the samples were analyzed by measuring UV absorbance at 258 nm in order to calculate the area ratio 220 nm / 258 nm.

The following results were obtained in the DPRA:

The test substance was dissolved in acetonitrile at a concentration of 100 mM. The samples of the test substance with the peptides were solutions at the time of preparation. Visual observation after the 24-hour incubation time did not reveal precipitates in any samples of the test substance with the peptides.

No co-elution of test substance and peptides was present.

The mean C-peptide depletion, caused by the test substance was determined to be - 0.12 %.

The mean K-peptide depletion, caused by the test substance was determined to be 0.08 %.

Negative depletions were considered to be “zero” for calculation of the mean peptide depletion, which was thus calculated to be 0.04 %.

Based on the observed results and applying the cysteine 1:10 / lysine 1:50 prediction model it was concluded that the test substance shows minimal or no chemical reactivity in the DPRA under the test conditions chosen.

Endpoint:
skin sensitisation: in vitro
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
May - Jun 2019
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to
Guideline:
OECD Guideline 442D (In Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method)
Version / remarks:
14 February 2017
Deviations:
no
GLP compliance:
yes (incl. certificate)
Remarks:
Landesamt für Umwelt Rheinland-Pfalz
Type of study:
activation of keratinocytes
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Expiration date of the lot/batch: 17 Jan 2020
- Physical state / color: solid, white
- Molecular weight: 261.794 g/mol
- Log Kow: - 0.77 (information provided by the sponsor)

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: ambient; under N2
- Solubility and stability of the test substance in the solvent/vehicle: The test substance was soluble in the vehicle.

TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The test substance was weighed and topped up with the chosen vehicle (4 % DMSO in culture medium 3) to achieve the required 4x concentration of the highest concentration (stock solution). Further concentrations were prepared as 4x concentrations by serial 1:1.2 dilution according to the planned concentrations (master plate). The test substance preparations were prepared by stirring.

FORM AS APPLIED IN THE TEST (if different from that of starting material) : solution
Details on study design:
Skin sensitisation (In vitro test system) - Details on study design:

PREPARATION OF THE CELLS
LuSens cells from the working cell bank were thawed and cultured using culture medium 1,
under standard culture conditions (37°C, ca. 5% CO2, ≥ 90% relative humidity) for at least
passage ≥5 but not longer than 15 passages prior to testing.
Before substance incubation, cells were seeded in 96-well microtiter plates (120 μL of
0.83 x 105 cells/mL cell suspension), using culture medium 2 for incubation for ca. 24 hours.
Two independent, valid experiments were performed. In each experiment, three replicates of each test-substance concentration were tested.

TEST SUBSTANCE APPLICATION FOR MTT AND LUCIFERASE ASSAY
After cell adaption for ca. 24 hours culture medium 2 was aspirated and replaced with 150 μL culture medium 3. The test substance was prepared as described in section 3.5.2. Each
preparation of the dilution plate was then applied in a ratio of 1:4 (50 μL) to the cells (final
DMSO concentration in the test medium = 1%).
After test-substance application the plates were sealed with plate sealers in order to prevent evaporation of the test substance. The plates were placed into the incubator under standard culture conditions for the exposure period of 48 ± 1 hours. For the luciferase assay a white plate (luminescence compatible plate) was used. In addition, a clear plate was treated in parallel for the determination of cell viability.

VISUAL INSPECTIONS
Each test-substance concentration was visually inspected directly after application and after the exposure period of 48 ± 1 hours in order to detect test-substance precipitates.

LUCIFERASE ASSAY
After visual inspection of the cells, the supernatant was aspirated from the white assay plate and discarded. The cells were washed twice with 300 μL PBS (with Ca2+/Mg2+). Subsequently 200 μL of One-Glo-preparation (= 100 μL One-Glo- Mix and 100 μL PBS (without Ca2+/Mg2+)) per well was added and cells were shaken on a plate shaker for ca. 10 min at room temperature in darkness. After the incubation the luminescence was measured in the luminometer.

CELL VIABILITY ASSAY MTT
Cell culture medium was aspirated from all wells. Thereafter 200 μL of a 0.5 mg/mL thiazolyl
blue tetrazolium bromide (MTT) solution (prepared 1:10 from a 5 mg/mL (MTT) stock solution
in PBS (without Ca2+/Mg2+) and culture medium 3) was added to each well of the 96-well
microtiter plate and incubated for at least further 2 hours in the incubator. For analysis, medium was aspirated and cells were lysed by adding 100 μL of lysis solution (99.6 mL DMSO; 10 g sodium dodecyl sulfate, SDS; and 0.4 mL glacial acetic acid). Absorbance was measured at 570 nm with reference wavelength 690 nm using a spectral-photometer.
Parameter:
other: CV75 [µM]
Run / experiment:
preliminary cytotoxicity assessment
Value:
1 092
Vehicle controls validity:
valid
Parameter:
other: mean fold induction
Run / experiment:
Experiment 1, plate 1
Value:
3.19
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Parameter:
other: mean fold induction
Run / experiment:
Experiment 1, plate 2
Value:
2.4
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Parameter:
other: mean fold induction
Run / experiment:
Experiment 2, plate 1
Value:
3.16
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Parameter:
other: mean fold induction
Run / experiment:
Experiment 2, plate 2
Value:
1.6
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Other effects / acceptance of results:
For calculation of mean fold induction the values with relative viability above 70 % were used.
The EC1.50 was calculated by linear regression from the results of the 171 µM and the 205 µM concentrations to be 187 µM.

Table 1: Results of preliminary cytotoxicity assessment

Concentration

(final test substance)

[µM]

Concentration

(test substance)

[µM]

Mean OD570-690of 3 replicates

Mean rel. viability

[%]

VC

0.5

1

5

10

50

100

500

1000

2000

VC

0.5

1

5

11

55

110

549

1098

2195

0.330

0.303

0.315

0.327

0.326

0.328

0.299

0.308

0.247

0.171

100.0

92.0

95.4

99.2

99.0

99.5

90.6

93.5

74.8

52.0

Table 2: Mean values and standard deviations of luciferase induction and rel. viability as well as p-values of t-test (experiment 1, plate 1)

Concentration

(test substance)

[µM]

Fold induction

Rel. viability [%]

t-test

Mean

SD

Mean

SD

p-value

Markers

613

735

882

1059

1270

1524

1829

2195

3.19

5.47

3.60

4.39

5.99

5.68

8.27

7.77

0.98

1.29

0.36

0.67

0.51

0.41

1.07

0.82

73

58

60

47

46

34

25

24

3

2

1

1

1

2

2

3

0.030

0.013

0.003

0.006

0.002

0.001

0.004

0.002

*

*

**

**

**

**

**

**

VC

EGDMA 90.8 µM

LA 5000 µM

1.00

4.94

0.78

0.14

0.17

0.02

100

95

101

4

9

6

-

0.021

0.000

-

*

**

Table 3: Mean values and standard deviations of luciferase induction and rel. viability as well as p-values of t-test (experiment 1, plate 2)

Concentration

(test substance)

[µM]

Fold induction

Rel. viability [%]

t-test

Mean

SD

Mean

SD

p-value

Markers

142

171

205

246

295

355

425

510

1.51

1.78

1.47

1.91

3.18

2.93

3.10

3.07

0.22

0.17

0.12

0.21

0.67

0.55

0.40

0.45

101

90

94

93

88

84

78

73

5

3

2

2

3

3

3

2

0.027

0.006

0.007

0.008

0.015

0.013

0.006

0.007

*

**

**

**

*

*

**

**

VC

EGDMA 90.8 µM

LA 5000 µM

1.00

5.55

0.87

0.10

0.66

0.09

100

93

97

3

2

3

-

0.000

0.012

-

**

*

Table 4: Mean values and standard deviations of luciferase induction and rel. viability as well as p-values of t-test (experiment 2, plate 1)

Concentration

(test substance)

[µM]

Fold induction

Rel. viability [%]

t-test

Mean

SD

Mean

SD

p-value

Markers

613

735

882

1059

1270

1524

1829

2195

3.16

3.10

3.87

7.70

8.73

8.71

8.78

8.27

0.41

0.48

0.60

1.61

0.60

0.77

0.15

1.60

73

68

66

54

51

38

30

36

0

3

1

2

2

1

2

1

0.005

0.008

0.007

0.009

0.001

0.002

0.000

0.008

**

**

**

**

**

**

**

**

VC

EGDMA 90.8 µM

LA 5000 µM

1.00

5.89

1.05

0.12

0.74

0.29

100

89

97

4

2

5

-

0.000

0.361

-

**

n.s.

Table 5: Mean values and standard deviations of luciferase induction and rel. viability as well as p-values of t-test (experiment 2, plate 2)

Concentration

(test substance)

[µM]

Fold induction

Rel. viability [%]

t-test

Mean

SD

Mean

SD

p-value

Markers

142

171

205

246

295

355

425

510

1.02

1.33

1.69

1.54

1.71

1.87

1.90

2.04

0.09

0.10

0.05

0.36

0.15

0.54

0.04

0.13

86

81

87

85

86

93

83

81

3

5

4

2

4

15

2

5

0.384

0.005

0.000

0.058

0.004

0.053

0.000

0.001

n.s.

**

**

n.s.

**

n.s.

**

**

VC

EGDMA 90.8 µM

LA 5000 µM

1.00

5.90

0.85

0.15

1.32

0.09

100

93

97

9

4

2

-

0.001

0.011

-

**

*

Conclusions:
Based on the results of this study, the test substance shows as a positive indication of keratinocyte activation.
No prediction can be made for skin sensitization according to GHS criteria based on the results of this in vitro study alone.
Executive summary:

The keratinocyte activating potential of the test substance was evaluated in the LuSens assay. For this purpose, the test substance was incubated with a luciferase reporter cell line (LuSens cells) for ca. 48 hours at 37 °C and antioxidant response element (ARE) dependent luciferase activity was measured in a luminometer.

In order to determine the concentrations suitable for the main experiment a pre-test (non-GLP) was performed. Cells were exposed to several concentrations of the test substance and cytotoxicity was determined by MTT assay. The CV75 value (= estimated concentration that affords 75 % cell viability) was determined by linear regression from the concentration-response

curve to be 1092 μM (corresponding to test substance as provided by the sponsor).

In the main test luciferase activity was measured after 48-hour exposure. In parallel a MTT assay was performed to assess cytotoxicity of the test substance. A total of 2 valid experiments were performed. The following results were observed:

The test substance was soluble in 4 % DMSO in culture medium 3 (4 x stock preparations) and in 1 % DMSO in culture medium 3 (final concentrations). No precipitates were noticed in any concentration after 48 hours.

The EC1.50 (the concentration resulting in a 1.50-fold luciferase induction) was calculated to be 187 μM (experiment 2). For the 1st experiment, calculation of an EC1.50 was not applicable.

In summary, after 48 hours of exposure to the test substance luciferase activity in LuSens cells was induced in at least two consecutive concentrations with statistical significance affording at least 70 % viability in at least two independent experiments. From this it has to be concluded that the test substance has a keratinocyte activating potential.

Endpoint:
skin sensitisation: in vitro
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
May - Jun 2019
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to
Guideline:
other: OECD Guideline 442E
Version / remarks:
25 Jun 2018
Deviations:
no
GLP compliance:
yes (incl. certificate)
Remarks:
Landesamt für Umwelt Rheinland-Pfalz
Type of study:
activation of dendritic cells
Specific details on test material used for the study:
SOURCE OF TEST MATERIAL
- Expiration date of the lot/batch: 17 Jan 2020
- Physical state / color: solid, white
- Molecular weight: 261.794 g/mol
- Log Kow: - 0.77 (information provided by the sponsor)

STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: ambient; under N2
- Solubility and stability of the test substance in the solvent/vehicle: The test substance was soluble in the vehicle.

TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The test substance was weighed and topped up with the chosen vehicle (culture medium) to achieve the required 2x concentration of the highest concentration (stock solution). Further concentrations were prepared as 2x concentrations by serial 1:1.2 dilution according to the planned concentrations in culture medium. The test substance preparations were prepared by stirring.

FORM AS APPLIED IN THE TEST (if different from that of starting material): solution
Details on study design:
Skin sensitisation (In vitro test system) - Details on study design:

PREPARATION OF THE CELLS
THP-1 cells from the working cell bank were thawed and cultured in suspension using complete RPMI 1640 medium supplemented with 10% fetal bovine serum (heat inactivated), 100 U/mL penicillin, 100 μg/mL streptomycin and 0.05 mM 2-mercaptoethanol under standard culture conditions (37°C, ca. 5% CO2, ≥ 90% relative humidity) until for 5 passages but not longer than passage 30 prior to testing.
Prior to use of the cells for a study, a reactivity check was performed with each new-thawed cells, as proposed in the OECD test guideline, using Nickel(II)sulfate hexahydrate, lactic acid and 1- chloro-2,4-dinitrobenzene in order to demonstrate qualification of the cells for the assay.
For substance incubation, cells were seeded in 24-well plates (500 μL of 2.0 x 106 cells/mL cell suspensions). Two independent, valid experiments were performed. In each experiment, duplicates of each test-substance concentration were tested.

TEST SUBSTANCE APPLICATION
Treatment was performed by adding 500 μL of test-substance preparation to the cells, thus
diluting the 2x concentrated test-substance preparations to their final concentration and the
cells to 1.0 x 106 cells/mL. After test-substance application the plates were sealed with plate sealers in order to prevent evaporation of the test substance. The plates were placed into the incubator under standard culture conditions for the exposure period of 24 ± 0.5 hours.

VISUAL INSPECTIONS
Each test-substance concentration was visually inspected directly after application and after the exposure period of 24 ± 0.5 hours in order to detect test-substance precipitates.

CELL STAINING AND FLOW CYTOMETRIC ANALYSIS
After visual inspection the cells were transferred into safe-lock tubes, collected by centrifugation and washed twice with 1 mL buffer. Cells were incubated with 600 μL of 0.01% Globulins Chon fraction II,III at 4°C for 15 min to block FC receptors (FcR). After FcR blocking, cells of each treatment condition were divided into 3 aliquots (approximately
0.3 x 106 cells/180 μL/group) in 96-well microtiter plates. Cells were centrifuged, supernatant was discarded and 50 μL working antibody solution was added to each pellet.
Cell staining was performed at 4°C for ca. 30 min in the dark. After staining the cells were
washed twice with 200 μL buffer and finally re-suspended in 200 μL buffer. Before analysis in flow cytometer the cells were stained with 5 μL of PI (50 μg/mL diluted in buffer) to yield a final concentration of 1.22 μg/mL PI.
Parameter:
other: CV75 [µg/mL]
Run / experiment:
preliminary cytotoxicity assessment
Value:
755
Vehicle controls validity:
valid
Parameter:
other: EC200% [µg/mL]
Run / experiment:
Experiment 1
Value:
386
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Parameter:
other: EC150% [µg/mL]
Run / experiment:
Experiment 2
Value:
532
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid
Parameter:
other: EC200% [µg/mL]
Run / experiment:
Experiment 2
Value:
492
Vehicle controls validity:
valid
Negative controls validity:
valid
Positive controls validity:
valid

Table 2: RFI CD86, RFI CD54 and rel. viability. Mean values and standard deviations of first experiment

Concentration

(test substance)

[µg/mL]

RFI CD86

RFI CD54

Viability

Mean [%]

SD [%]

Mean [%]

SD [%]

Rel. viability [%]

SD of viability

253

303

364

437

524

629

755

906

96

112

126

112

141

127

115

91

1

7

3

3

2

10

20

18

171

171

182

241

258

283

290

342

29

29

37

40

65

30

57

152

99

98

96

93

89

82

72

65

1

1

1

1

2

3

5

6

VC

LA 1000 µg/mL

DNCB 4 µg/mL

100

67

302

18

8

7

100

153

667

47

25

56

100

100

84

0

0

6

Table 3: RFI CD86, RFI CD54 and rel. viability. Mean values and standard deviations of second experiment

Concentration

(test substance)

[µg/mL]

RFI CD86

RFI CD54

Viability

Mean [%]

SD [%]

Mean [%]

SD [%]

Rel. viability [%]

SD of viability

253

303

364

437

524

629

755

906

107

126

126

132

149

167

152

89

1

23

11

4

17

8

12

22

148

143

157

174

215

276

320

760

33

26

34

23

33

1

5

367

98

97

95

91

86

78

66

58

0

1

1

2

3

4

2

6

VC

LA 1000 µg/mL

DNCB 4 µg/mL

100

81

386

6

11

94

100

128

1121

24

18

239

100

100

64

0

0

11

Conclusions:
Based on the results of this study, the test substance shows as a positive indication of dendritic cell activation.
No prediction can be made for skin sensitization according to GHS criteria based on the results of this in vitro study alone.
Executive summary:

The potential of the test substance to induce the cell membrane markers CD86 and CD54 expression was evaluated in the Human Cell Line Activation Test (h-CLAT). For this purpose, the test substance was incubated with human monocytic leukemia cell line THP-1 for ca. 24 hours at 37 °C and membrane marker expression (CD86 / CD54) was measured by flow cytometry.

In order to determine the concentrations suitable for the main experiment a pre-test (non-GLP) was performed. Cells were exposed to several concentrations of the test substance and cytotoxicity was determined thereafter by propidium iodide (PI) intercalation into the DNA. The CV75 value (= estimated concentration that affords 75 % cell viability) was determined by linear regression from the concentration-response curve to be 755 μg/mL (corresponding to test substance as provided by the sponsor).

In the main test after 24-hour exposure THP-1 cells were stained with FITC labeled anti-human-CD86/ anti-human-CD54 antibody and propidium iodide and the fluorescence intensity was analyzed using flow cytometry. A total of 2 valid experiments were performed. The following results were observed:

The test substance was soluble in culture medium (2 x stock preparations and final concentrations). No precipitates were noticed in any concentration after 24 hours.

The EC150 % (the concentration resulting in a RFI of 150 %) for CD86 was calculated to be 532 μg/mL (experiment 2). For the 1st experiment, calculation of an EC150 % was not applicable.

The EC200 % (the concentration resulting in a RFI of 200 %) for CD54 was calculated to be 386 μg/mL (experiment 1) and 492 μg/mL (experiment 2), respectively.

In summary, after 24 hours of exposure to the test substance CD54 expression was induced in THP-1 cells affording at least 50 % viability in at least two independent experiments. From this it has to be concluded that the test substance induces dendritic cell activation.

Endpoint conclusion
Endpoint conclusion:
adverse effect observed (sensitising)
Additional information:

The objective was to assess the skin sensitizing potential of the test substance. A combination of the following three in vitro methods, addressing key events of the adverse outcome pathway (AOP) for skin sensitization (OECD, 2012) as defined by the OECD, were part of this in vitro Skin Sensitization Turnkey Testing Strategy:

- protein reactivity (DPRA)

- activation of keratinocytes (LuSens), and

- activation of dendritic cells (h-CLAT).

DPRA

The reactivity of the test substance towards synthetic cysteine (C)- or lysine (K)-containing peptides was evaluated in the Direct Peptide Reactivity Assay (DPRA). For this purpose, the test substance was incubated with synthetic peptides for ca. 24 hours at ca. 25°C and the remaining non-depleted peptide concentrations were determined by high performance liquid chromatography (HPLC) with gradient elution and UV-detection at 220 nm.

The test substance was dissolved at 100 mM in acetonitrile. Three samples of the test substance were incubated with each peptide in ratios of 1:10 (for C-containing peptide) or 1:50 (for K-containing peptide). Additionally, triplicates of the concurrent vehicle control (= VC) were incubated with the peptides.

Further, in order to detect possible interference of the test substance with the peptides, a coelution control was performed and the samples were analyzed by measuring UV absorbance at 258 nm in order to calculate the area ratio 220 nm / 258 nm.

The following results were obtained in the DPRA:

The test substance was dissolved in acetonitrile at a concentration of 100 mM. The samples of the test substance with the peptides were solutions at the time of preparation. Visual observation after the 24-hour incubation time did not reveal precipitates in any samples of the test substance with the peptides.

No co-elution of test substance and peptides was present.

The mean C-peptide depletion, caused by the test substance was determined to be - 0.12 %.

The mean K-peptide depletion, caused by the test substance was determined to be 0.08 %.

Negative depletions were considered to be “zero” for calculation of the mean peptide depletion, which was thus calculated to be 0.04 %.

Based on the observed results and applying the cysteine 1:10 / lysine 1:50 prediction model it was concluded that the test substance shows minimal or no chemical reactivity in the DPRA under the test conditions chosen.

LuSens

The keratinocyte activating potential of the test substance was evaluated in the LuSens assay. For this purpose, the test substance was incubated with a luciferase reporter cell line (LuSens cells) for ca. 48 hours at 37 °C and antioxidant response element (ARE) dependent luciferase activity was measured in a luminometer.

In order to determine the concentrations suitable for the main experiment a pre-test (non-GLP) was performed. Cells were exposed to several concentrations of the test substance and cytotoxicity was determined by MTT assay. The CV75 value (= estimated concentration that affords 75 % cell viability) was determined by linear regression from the concentration-response

curve to be 1092 μM (corresponding to test substance as provided by the sponsor).

In the main test luciferase activity was measured after 48-hour exposure. In parallel a MTT assay was performed to assess cytotoxicity of the test substance. A total of 2 valid experiments were performed. The following results were observed:

The test substance was soluble in 4 % DMSO in culture medium 3 (4 x stock preparations) and in 1 % DMSO in culture medium 3 (final concentrations). No precipitates were noticed in any concentration after 48 hours.

The EC1.50 (the concentration resulting in a 1.50-fold luciferase induction) was calculated to be 187 μM (experiment 2). For the 1st experiment, calculation of an EC1.50 was not applicable.

In summary, after 48 hours of exposure to the test substance luciferase activity in LuSens cells was induced in at least two consecutive concentrations with statistical significance affording at least 70 % viability in at least two independent experiments. From this it has to be concluded that the test substance has a keratinocyte activating potential.

h-CLAT

The potential of the test substance to induce the cell membrane markers CD86 and CD54 expression was evaluated in the Human Cell Line Activation Test (h-CLAT). For this purpose, the test substance was incubated with human monocytic leukemia cell line THP-1 for ca. 24 hours at 37 °C and membrane marker expression (CD86 / CD54) was measured by flow cytometry.

In order to determine the concentrations suitable for the main experiment a pre-test (non-GLP) was performed. Cells were exposed to several concentrations of the test substance and cytotoxicity was determined thereafter by propidium iodide (PI) intercalation into the DNA. The CV75 value (= estimated concentration that affords 75 % cell viability) was determined by linear regression from the concentration-response curve to be 755 μg/mL (corresponding to test substance as provided by the sponsor).

In the main test after 24-hour exposure THP-1 cells were stained with FITC labeled anti-human-CD86/ anti-human-CD54 antibody and propidium iodide and the fluorescence intensity was analyzed using flow cytometry. A total of 2 valid experiments were performed. The following results were observed:

The test substance was soluble in culture medium (2 x stock preparations and final concentrations). No precipitates were noticed in any concentration after 24 hours.

The EC150 % (the concentration resulting in a RFI of 150 %) for CD86 was calculated to be 532 μg/mL (experiment 2). For the 1st experiment, calculation of an EC150 % was not applicable.

The EC200 % (the concentration resulting in a RFI of 200 %) for CD54 was calculated to be 386 μg/mL (experiment 1) and 492 μg/mL (experiment 2), respectively.

In summary, after 24 hours of exposure to the test substance CD54 expression was induced in THP-1 cells affording at least 50 % viability in at least two independent experiments. From this it has to be concluded that the test substance induces dendritic cell activation.

Based on the results and applying the evaluation criteria, the test substance is not peptide reactive, activates keratinocytes and activates dendritic cells. Applying the evaluation criteria, the test substance is predicted to be a skin sensitizer.

Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
no study available

Justification for classification or non-classification

Classification, Labelling, and Packaging Regulation (EC) No. 1272/2008

The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. In an In Vitro Skin Sensitization Turnkey Test Strategy the test results of two out of three in vitro tests were determined to be positive with the test substance. Therefore, the test substance is considered to be classified for skin sensitization Cat. 1 under Regulation (EC) No. 1272/2008, as amended for the thirteenth time in Regulation (EC) No. 2018/1480.